Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.46 |
| ▸ | FDPS | P14324 | 3/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.32 |
| ▸ | SGPL1 | O95470 | 4/20 | 0.31 |
| ▸ | LAP3 | P28838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8165767 | 0.91 | PTPN1 (0.50) | PTPN1SMPD1 | |
| SCHEMBL7156062 | 0.82 | PTPN1 (0.41) | PTPN1SMPD1FDPS | |
| SCHEMBL11619477 | 0.82 | SMPD1 (0.69) | PTPN1SMPD1FDPSS1PR2S1PR1 | |
| SCHEMBL2370055 | 0.82 | SMPD1 (0.69) | PTPN1SMPD1FDPSS1PR2S1PR1 | |
| SCHEMBL2514364 | 0.82 | SMPD1 (0.69) | PTPN1SMPD1FDPSS1PR2S1PR1 | |
| SCHEMBL28470942 | 0.82 | SMPD1 (0.69) | PTPN1SMPD1FDPSS1PR2S1PR1 | |
| SCHEMBL11845935 | 0.81 | SMPD1 (0.68) | PTPN1SMPD1FDPSS1PR2S1PR1 | |
| SCHEMBL28701575 | 0.80 | SMPD1 (0.67) | PTPN1SMPD1FDPSS1PR2S1PR1 | |
| Ammonia Solution, Strong SCHEMBL28408668 | 0.80 | SMPD1 (0.67) | PTPN1SMPD1FDPSS1PR2S1PR1 | |
| SCHEMBL8682289 | 0.79 | SMPD1 (0.66) | PTPN1SMPD1FDPSS1PR2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772469-B2 | Synthetic double-stranded oligonucleotides for specific inhibition of gene expression | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| EP-1409670-B1 | SYNTHETIC DOUBLE STRANDED OLIGONUCLEOTIDES FOR TARGETED INHIBITION OF GENE EXPRESSION | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-10-13 | — | — | EP | disclosed |
| EP-1409670-A2 | SYNTHETIC DOUBLE STRANDED OLIGONUCLEOTIDES FOR TARGETED INHIBITION OF GENE EXPRESSION | Aventis Pharma Deutschland GmbH (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-20030139585-A1 | Synthetic double-stranded oligonucleotides for specific inhibition of gene expression | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-24 | — | — | US | disclosed |
| WO-2003008576-A2 | SYNTHETIC DOUBLE STRANDED OLIGONUCLEOTIDES FOR TARGETED INHIBITION OF GENE EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139585-A1 | Synthetic double-stranded oligonucleotides for specific inhibition of gene expression | DCLRE1B, RIOX2, SRRT | PTPN1 3694/4885SMPD1 3336/4885FDPS 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.